GAIN THERAPEUTICS INC (GANX)

US36269B1052 - Common Stock

3.21  +0.01 (+0.31%)

GAIN THERAPEUTICS INC

NASDAQ:GANX (9/27/2023, 8:28:11 PM)

3.21

+0.01 (+0.31%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-10 2023-08-10/bmo
Earnings (Next)11-08 2023-11-08/amc
Ins Owners2.19%
Inst Owners10.95%
Market Cap40.77M
Shares12.70M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts86
IPO03-18 2021-03-18
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

GANX Daily chart

Company Profile

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. The company is headquartered in Bethesda, Maryland and currently employs 28 full-time employees. The company went IPO on 2021-03-18. The firm is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. Its drug discovery platform, Site-Directed Enzyme Enhancement Therapy (SEE-Tx), to discover novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of GCase function, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.

Company Info

GAIN THERAPEUTICS INC

4800 Hampden Lane, Suite 200

Bethesda MARYLAND 20814

P: 13015001556.0

CEO: Eric Richman

Employees: 28

Website: https://www.gaintherapeutics.com/

GANX News

News Image2 days ago - Gain Therapeutics, Inc.Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023
News Image2 days ago - Gain Therapeutics, Inc.Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023

BETHESDA, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery...

News Image7 days ago - Gain Therapeutics, Inc.Gain Therapeutics to Present at the Cambridge Healthtech Institute’s 2nd Annual Neurodegeneration Targets Conference
News Image7 days ago - Gain Therapeutics, Inc.Gain Therapeutics to Present at the Cambridge Healthtech Institute’s 2nd Annual Neurodegeneration Targets Conference

BETHESDA, Md., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the...

News Image9 days ago - Seeking AlphaCLNE, QDEL and SOUN are among after hour movers (NASDAQ:GANX)

Gainers: Gain Therapeutics (GANX) +7%. QuidelOrtho  (QDEL) +5%

News Image16 days ago - Gain Therapeutics, Inc.Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia

GANX Twits

Here you can normally see the latest stock twits on GANX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example